TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients with molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants who Achieve Minimal Disease Activity (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early surgical site occurrences or wound related events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of I-gel insertion attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Final I-gel insertion time taken duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Agreement of thermographic images for diagnosis of periodontal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SADE and ADE
Endpoint domain: Adverse events/effects
Primary endpoint: Generalized Anxiety Disorder 7-item (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-operative surgical morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative surgical mortality
Endpoint domain: Mortality/survival
Primary endpoint: Aesthetic satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Speech-in-noise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Assessment of Cognition in Schizophrenia (BACS App) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Depressive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in awe levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute variation in interferon signature (IFN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Polyps Severity Index (PSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new thrombotic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quadrant dominance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body effective dose (in rems)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation doses (rems) to critical organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recovery of study product in infant feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean 24 hours diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 24 hours mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in accelerometry-measured physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absolute Change in Post-Inflammatory Hyperpigmentation Overall Disease Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Aerosolization of particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Awareness of hypertensive disorders of pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the online ACT program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the online ACT program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Reported Participant Tobacco Cessation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Carbon Monoxide (CO) Verification of Tobacco Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-PCI myocardial infarction or myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in YGTSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with negative HPV PCR sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sport enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of molecular alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of renal colic and urolithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Depression Severity (self-report)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression Severity (observer-rated)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lactulose mannitol ratio (LMR) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sorenson Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in axial length of the eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a diagnosis of CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients with ACR test in the last 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FAPI uptake on PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥Grade 2 proctitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Elderspeak Measured by Diminutives
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Treatment-Emergent Adverse Events Withdrawals
Endpoint domain: Adverse events/effects
Primary endpoint: Change in GI Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical Activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of sleep changes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Body composition - Body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of spontaneous myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of sofosbuvir/daclatasvir combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Obstetric Quality of Recovery score (ObsQoR-11) on postpartum 1st day
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Obstetric Quality of Recovery score (ObsQoR-11) on postpartum 2nd day
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of treatment-related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: MEV90 of 0.5% Ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood ionized calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Continued Access to Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hand control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cervical spine sagittal alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major clinical outcomes in acute stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tsui test motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epidural waveform test (catheter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient State index (PSi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram (EEG) power spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of luteinizing hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of Follicle-stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of Free androgen index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Dose Limiting Toxicities of ZL-1310
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Adverse Events of ZL-1310
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Events of ZL-1310
Endpoint domain: Adverse events/effects
Primary endpoint: Objective performance in Math Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of a vIGA-AD Score of 0 or 1 with a ≥2 Point Reduction From Baseline at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of ≥ 75% Reduction From Baseline in EASI Score (EASI 75) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Consultation of Incontinence Questionnaire - Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: King's Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incontinence Impact Questionnaire short form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PE / DVT sensitivity of the clinical decision support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PE / DVT specificity of the clinical decision support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PE / DVT negative predictive value of the clinical decision support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patients mobilised at lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patients mobilised at breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed (rescheduled) well child visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: transfer to intensive care unit (ICU)
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of success of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success after full pulpotomy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic success after full pulpotomy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Short Form 36 Health Survey Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lean and fat mass content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short Physical Performance Battery (for mobility evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative weeks with platelet count ≥30×10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with unsolicited systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: At least two-grade improvement in IGA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RVCreserve measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: macular ganglion cell thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dysphotopsia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Registration of plasma cell disorder patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Central Nervous System Objective Response Rate (CNS ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Awareness and knowledge of gynecologists
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concordance of global quality of images
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fentanyl plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SBRT as bridging therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Green Space Use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in % time in glucose range [3.9-10.0 mmol/l]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequencies of exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fecal RNA virus clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Falls
Endpoint domain: Mortality/survival
Primary endpoint: Change in General Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Victorian Institute of Sport Assessment - Achilles (VISA-A) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Pain Interference Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' knowledge of foot self-care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' practice of foot self-care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Barriers to foot self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of patients diagnosed with pulmonary infection
Endpoint domain: Adverse events/effects
Primary endpoint: Joint Position Sense Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Gastrocnemius Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of Plantar Fascia Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Straight Leg Lift Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major pathologic response (mPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine leiomyoma-related symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous (IV) line placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aggressive Responding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Acne Grading System (GAGS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectroscopy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with supplementation-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Schirmer's Test (without anesthesia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patients' stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' satisfaction of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appropriateness of venous thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Force (Newtons) Required to Dislodge an IV Catheter in retrograde direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force (Newtons) Required to Dislodge an IV Catheter in 90 degrees direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of evaluation method for portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hearing threshold at a frequency of 125 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hearing threshold at a frequency of 250 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hearing threshold at a frequency of 500 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hearing threshold at a frequency of 750 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hearing threshold at a frequency of 1000 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of pre-op treatment and proceeding to surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of autoimmune antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Renal Function at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Cardiac Structure at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical activity level (total score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical activity level (classification of physical activity level)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activity tracker wear rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of computer vision assessment of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Do step counts predict quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC0-12 of Obeldesivir (ODV) Metabolite, GS-441524
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ODV Metabolite, GS-441524
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough of ODV Metabolite, GS-441524
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) by Day 35
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities by Day 35
Endpoint domain: Adverse events/effects
Primary endpoint: Increased Lower Body Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increased Maximum Voluntary Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increased Upper Body Muscle Strength and Explosiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients dropping out of study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal self well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vertical Marginal bone loss in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative wound area reduction (RWAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lower limits of autoregulation (LLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension angle displayed by the Mako robot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronal hip-knee-ankle (HKA) angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NFOSI-18 Function/Well-being subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Decoy20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily time spent standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes